FMT therapy has demonstrated patient benefits for inflammatory bowel disease (IBD) [1]. In the double-blind, randomised controlled LOTUS trial (ACTRN12619000611123), Dr Craig Haifer (University of Sydney, Australia) and colleagues investigated the effects of orally administered FMT therapy after a pre-treatment of antibiotics (n=15) versus treatment with antibiotics alone (n=20) in patients with mild-to-moderate UC [2]. Subsequently, FMT responder were re-randomised to FMT maintenance therapy (n=4) or FMT withdrawal (n=6). The primary endpoint was steroid-free clinical remission and endoscopic remission/response at week 8 and week 56 for induction therapy and maintenance therapy respectively.
The primary endpoint was met for 54% of the patients in the FMT arm versus 15% of the patients in the placebo arm. Clinical remission rates were 73% for patients receiving FMT therapy and 25% for patients receiving placebo. All patients enrolled in the maintenance FMT therapy showed clinical and endoscopic remission at week 56, whereas all patients randomised to FMT withdrawal experienced disease flare. In addition, IBD questionnaire scores demonstrated a reduced quality of life for patients in the withdrawal arm compared with patients in the maintenance arm.
Adverse events occurred in 47% of the patients in the FMT arm and in 90% of the patients in the placebo arm. There were 2 cases of severe adverse events in both arms of the trial. Dr Haifer concluded that FMT therapy was well tolerated and feasible in this population. Furthermore, he argued that the potential enhanced efficacy of FMT therapy due to pre-treatment with antibiotics should be investigated in-depth.
- Paramsothy S, et al. J Crohns Colitis 2017;11(10):1180-1199.
- Haifer C, et al. Lyophilised Orally administered FMT therapy in Ulcerative colitis (LOTUS) study. OP30, ECCO 2021 Virtual Congress, 2-3 & 8-10 July.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Extracellular RNA has potential as a non-invasive biomarker in IBD Next Article
Echocardiography identifies risks of arrhythmia, cardiac failure in pediatric myocarditis »
« Extracellular RNA has potential as a non-invasive biomarker in IBD Next Article
Echocardiography identifies risks of arrhythmia, cardiac failure in pediatric myocarditis »
Table of Contents: ECCO 2021
Featured articles
Biologics Updates
Similar efficacy of ustekinumab and adalimumab for moderate-to-severe CD
Ustekinumab safe and effective in elderly CD patients
Early clinical remission and response following risankizumab therapy in CD
Risk of hospitalisation and surgery linked to IBD biological
Obesity increases the risk of immunogenicity to adalimumab in IBD
Improvements in Small Molecules
Upadacitinib meets primary endpoint for moderate-to-severe UC
Promising safety and pharmacokinetic data on BT051 for UC
Surgical closure plus anti-TNF outperforms anti-TNF alone for perianal fistula
Novel Biomarkers
Blood proteins predicting relapse in CD identified
Extracellular RNA has potential as a non-invasive biomarker in IBD
Risk Mitigation
No increased risk of (severe) COVID-19 among IBD patients
Oral faecal microbiota transplant therapy efficacious in UC
Artificial intelligence outperforms human classifying of endoscopic images in UC
Increased risk of rectal cancer after colectomy in IBD
Risk of colorectal cancer is detected by low-pass whole genome sequencing
Large variability in IBD care and education across Europe
Ultra-processed food intake associated with IBD
Factors of coping difficulties in IBD revealed
Related Articles

November 28, 2024
TL1A inhibitor tulisokibart shows potential in UC
May 9, 2019
IBD risk of treatment with IL-17 antagonists
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com